Menu icon to display side navigation Globe icon to display foreign language website menu Close icon to hide foreign language website menu
Austrian flag German flag Hong Kong flag Irish flag Russian flag South African flag Turkish flag

FAQ

1. What is FLEXISEQ®?

2. What is the difference between FLEXISEQ® Osteoarthritis, FLEXISEQ® Active and FLEXISEQ® Sport?

3. Which FLEXISEQ® product should I choose?

4. Where can I purchase FLEXISEQ®?

5. How much does FLEXISEQ® cost?

6. What is the reason for the difference in price between FLEXISEQ® and FLEXISEQ® Active?

7. Can FLEXISEQ® products be prescribed by my doctor?

8. What is in the FLEXISEQ® products?

9. How well do the FLEXISEQ® products work?

10. What are the commonly reported side effects?

11. I have experienced a reaction to FLEXISEQ®; should I stop treatment?

12. How should I apply the gel?

13. What should I do if the product is applied incorrectly?

14. How often should I apply FLEXISEQ® products?

15. Can I alter treatment regimen to, say, every second day?

16. What are the differences between FLEXISEQ® and other pain treatments?

17. How well does FLEXISEQ® work compared with other topical products used for the same purpose?

18. How does FLEXISEQ® work?

19. What is the evidence that the Sequessome™ vesicles get into the joint?

20. Do all three products work in the same way?

21. How quickly does FLEXISEQ® work?

22. How long can I use FLEXISEQ® for?

23. What is the longest time that any patient has been treated for with FLEXISEQ®

24. How long does the pain relief last once treatment is stopped?

25. Are FLEXISEQ® products right for me?

26. Can FLEXISEQ® products be used in patients with other disorders such as MS, diabetes?

27. Can FLEXISEQ® be used alongside medications?

28. What is the total number of patients treated with FLEXISEQ®?

29. How have the safety and efficacy of FLEXISEQ® products been studied?

30. Why aren't there any studies on the hands or other joints?

31. Is FLEXISEQ® as effective on other joints as it is on the knee?

32. Can FLEXISEQ® be used on joints other than the knee?

33. How should I store FLEXISEQ®?

34. I have not received any beneficial effect from these products – why?

35. Can I use body lotions, etc.?

36. Can FLEXISEQ® products be used in pregnancy or breastfeeding?

37. Is it available in all markets in Europe?

38. What is the regulatory status of FLEXISEQ®?

39. What company is marketing FLEXISEQ®?

40. Where is FLEXISEQ® manufactured?

41. Who should I report concerns or product issues to?

42. Please may I have the Summary of Product Characteristics for FLEXISEQ®?

Section B

1. How does FLEXISEQ® Sport meet the needs of elite sportsmen and women?

2. Is FLEXISEQ® Sport the right product for me?

3. Do FLEXISEQ® Sport constituents appear on the World Anti-Doping Agency (WADA) list of prohibited substances?

4. FLEXISEQ® Sport is a non-drug treatment and its ingredients are not prohibited by WADA, so why run the product through an anti-doping screen?

5. What does batch testing of FLEXISEQ® Sport entail?

6. How can I confirm that my tube has been tested and cleared?

7. Who from the world of sports is benefiting from FLEXISEQ® Sport?

8. Who are the FLEXISEQ® Sport Ambassadors?

See Our Range Of Products

i Kneer W, Seidel EJ, Mazgareanu S, Rother M. J Pain Res 2013;6:743-753

ii Conaghan P, Dickson J, Bolten W, Cevc G, Rother M. Rheumatology 2013 Jul; 52(7):1303-12

iii Rother M, Conaghan PG. J Rheumatology 2013 2013;40:1742-48

iv NICE, 2008. Available at: www.nice.org.uk/CG059 (accessed 27 February 2012).

v McKenzie S, Torkington A. Aust Fam Physician 2010;39(9):622–625.

vi Coxib and Traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;pii: Q5 S0140-6736(13)60900-9

vii Fosbøl EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009;85:190-7

viii Hills BA, Monds MK. Br J Rheumatol 1998;37:143–147.

ix Vecchio P, Thomas R, Hills BA. Surfactant treatment for osteoarthritis. Rheumatology 1999;38:1020−1021

x Yurdakul S, Baverstock N, Mills J. Localisation of fluorescently labelled drug-free phospholipid vesicles to the cartilage surface of rat synovial joints. ICOOMD, London 2015

xi Clinical study report (sponsor code CL-033-III-05). IDEA AG, Frankfurter Ring 197a, 80807 Munich, Germany. 15 December 2008

xii Rother M, Yeoman G, Ekman E. Annual EULAR Congress 2012b Abstract no. EULAR12-3375

xiii National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), 2010. Osteoarthritis. Available at: www.niams.nih.gov/health_info/osteoarthritis/ (accessed 27 February 2012).

xiv Kneer W, et al. Curr Drug Saf 2009;4:5–10.